
FDA Approves Gene Therapy for Deafness: Impact & Cost
The FDA has approved Otarmeni, the first gene therapy for inherited hearing loss, targeting mutations in the OTOF gene. Clinical trials showed significant hearing improvements in treated children, with some experiencing near-normal hearing restoration. Notably, Regeneron announced that the therapy will be provided free of charge to US patients, challenging the typical multi-million dollar pricing model for rare gene therapies. Experts anticipate this breakthrough will catalyze further research and investment into treating various forms of genetic deafness. The treatment is administered via a surgery similar to cochlear implantation.






















